Omega-3 Lipid Mediators: Modulation of the M1/M2 Macrophage Phenotype and Its Protective Role in Chronic Liver Diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and preclinical data without systematic methodology or original human data
PubMed 37958514 · doi:10.3390/ijms242115528
What was done
This narrative review analyzed published evidence on the roles and molecular mechanisms of omega-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) and their specialized pro-resolving mediators (resolvins, protectins, maresins) in modulating M1/M2 macrophage phenotypes and inflammatory resolution in chronic liver diseases such as nonalcoholic fatty liver disease and cirrhosis.
What was found
The abstract reports no numerical data or effect sizes. Qualitatively, it reports that EPA, DHA, and specialized pro-resolving mediators promote a shift toward an M2 anti-inflammatory phenotype, facilitate apoptotic cell phagocytosis, and promote tissue repair. Maresin 1 (MaR1) specifically demonstrates hepatoprotective effects by promoting M2 polarization, reducing oxidative stress, and inhibiting NF-κB inflammatory signaling.
Why it matters
It synthesizes the mechanistic pathways through which omega-3-derived pro-resolving mediators regulate macrophage polarization as potential therapeutic targets for chronic hepatic inflammation.
Limits
The review relies on preclinical mechanistic models without presenting original clinical trial data or quantitative effect sizes in the abstract. Methodological details, search criteria, and human clinical efficacy are not reported.
Cited by
- supports Metabolites of EPA and DHA include resolvins and protectins, which function to resolve inflammatory processes.